Form 8-K - Current report:
SEC Accession No. 0001104659-25-042841
Filing Date
2025-05-01
Accepted
2025-05-01 06:00:38
Documents
16
Period of Report
2025-04-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2513759d1_8k.htm   iXBRL 8-K 36724
2 EXHIBIT 10.1 tm2513759d1_ex10-1.htm EX-10.1 76868
3 EXHIBIT 99.1 tm2513759d1_ex99-1.htm EX-99.1 22571
7 GRAPHIC tm2513759d1_ex99-1img01.jpg GRAPHIC 4775
  Complete submission text file 0001104659-25-042841.txt   334317

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA fold-20250428.xsd EX-101.SCH 3044
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE fold-20250428_lab.xml EX-101.LAB 34239
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fold-20250428_pre.xml EX-101.PRE 22378
18 EXTRACTED XBRL INSTANCE DOCUMENT tm2513759d1_8k_htm.xml XML 3552
Mailing Address 47 HULFISH STREET PRINCETON NJ 08542
Business Address 47 HULFISH STREET PRINCETON NJ 08542 (609) 662-2000
AMICUS THERAPEUTICS, INC. (Filer) CIK: 0001178879 (see all company filings)

EIN.: 200422823 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33497 | Film No.: 25899097
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)